In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it could change the future of prostate cancer testing. Klotz is a professor of surgery at the University of Toronto, and the chair of prostate cancer research at the Sunnybrook Health Sciences Centre, Ontario, Canada.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.